For sales

Highlights from the Week of 6th April 2026 – 13th April 2026 in the world of pharma and healthcare! 

Highlights from the Week of 6th April 2026 - 13th April 2026 ( Launch ) Ascendis Pharma launches the once-weekly YUVIWEL in the US for achondroplasia with open epiphyses to provide continuous systemic exposure to CNP ( EU, Approval ) EC grants approval to Sanofi and Regeneron's DUPIXENT, a IL4 and IL13 signal inhibitor to treat moderate-to-severe chronic spontaneous urticaria in children aged 2 to 11 years ( MHRA, Approval ) MHRA accepts Savara's MOLBREEVI application for marketing authorization indicated to treat autoimmune pulmonary alveolar proteinosis ( FDA, Fast Track ) Climb Bio obtains FDA Fast Track Designation for budoprutug, an anti-CD19 monoclonal antibody, for the treatment of primary membranous nephropathy Pg 1/2 All logos and trademarks remain the intellectual properties of their respective owners
Download

Connect with us

Please fill in the information below, and we'll get back to you.